Diagnosis for latent tuberculosis infection: new alternatives

C Carranza, S Pedraza-Sanchez… - Frontiers in …, 2020 - frontiersin.org
Latent tuberculosis infection (LTBI) is a subclinical mycobacterial infection defined on the
basis of cellular immune response to mycobacterial antigens. The tuberculin skin test (TST) …

Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection

JD Simmons, CM Stein, C Seshadri, M Campo… - Nature Reviews …, 2018 - nature.com
Mycobacterium tuberculosis is a leading cause of mortality worldwide and establishes a
long-lived latent infection in a substantial proportion of the human population. Multiple lines …

[HTML][HTML] A functional role for antibodies in tuberculosis

LL Lu, AW Chung, TR Rosebrock, M Ghebremichael… - Cell, 2016 - cell.com
While a third of the world carries the burden of tuberculosis, disease control has been
hindered by a lack of tools, including a rapid, point-of-care diagnostic and a protective …

Robust IgM responses following intravenous vaccination with Bacille Calmette–Guérin associate with prevention of Mycobacterium tuberculosis infection in …

EB Irvine, A O'Neil, PA Darrah, S Shin… - Nature …, 2021 - nature.com
Abstract Development of an effective tuberculosis (TB) vaccine has suffered from an
incomplete understanding of the correlates of protection against Mycobacterium tuberculosis …

What have we learnt about BCG vaccination in the last 20 years?

HM Dockrell, SG Smith - Frontiers in immunology, 2017 - frontiersin.org
A number of new tuberculosis (TB) vaccines have been or are entering clinical trials, which
include genetically modified mycobacteria, mycobacterial antigens delivered by viral …

Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease

TJ Scriba, A Penn-Nicholson, S Shankar… - PLoS …, 2017 - journals.plos.org
Our understanding of mechanisms underlying progression from Mycobacterium tuberculosis
infection to pulmonary tuberculosis disease in humans remains limited. To define such …

Key advances in vaccine development for tuberculosis—Success and challenges

R Lai, AF Ogunsola, T Rakib, SM Behar - NPJ vaccines, 2023 - nature.com
Breakthrough findings in the clinical and preclinical development of tuberculosis (TB)
vaccines have galvanized the field and suggest, for the first time since the development of …

Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial

M Tameris, H Mearns, A Penn-Nicholson… - The lancet Respiratory …, 2019 - thelancet.com
Background Infants are a key target population for new tuberculosis vaccines. We assessed
the safety and immunogenicity of the live-attenuated Mycobacterium tuberculosis vaccine …

Accelerating research and development of new vaccines against tuberculosis: a global roadmap

F Cobelens, RK Suri, M Helinski… - The Lancet Infectious …, 2022 - thelancet.com
To eliminate tuberculosis globally, a new, effective, and affordable vaccine is urgently
needed, particularly for use in adults and adolescents in low-income and middle-income …

Moving tuberculosis vaccines from theory to practice

P Andersen, TJ Scriba - Nature Reviews Immunology, 2019 - nature.com
Tuberculosis (TB) vaccine research has reached a unique point in time. Breakthrough
findings in both the basic immunology of Mycobacterium tuberculosis infection and the …